Oncolytics Biotech (ONCY) Reports Q2 Loss of $0.13/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Oncolytics Biotech (ONCY) Reports Q2 Loss of $0.13/sh

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results

August 6, 2021 7:00 AM EDT

- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer

- Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021

- Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types

- Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023

- Management hosting conference call and webcast today at 8:00... More